Mr. Cali is a Managing Partner at Noble Capital Markets, Inc. Nathan Cali has more than 19 years of combined healthcare, biotechnology, and pharmaceutical experience. He has led the Healthcare Investment Banking franchise at Noble since 2017 and, was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), and medical devices. Mr. Cali is a Board Member of Precise Bio, a tissue engineering, biomaterials, cell technologies, including, cardiology, orthopedics, and dermatology. He was previously a Board observer of Eledon Pharmaceuticals (ELDN:NASDAQ, f.k.n.a. Anelixis Therapeutics, Inc.), a phase II biotechnology company pursuing transplant, autoimmune, and neurology treatments. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization. Mr. Cali has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal for his work as a sells-side analyst. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.

Francisco Penafiel has more than 22 years of experience in areas such as investment banking, valuation advisory services, mergers and acquisitions and portfolio management. He joined Noble Capital Markets in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science.

Prior to joining the investment banking department at Noble in 2011, Francisco was part of Noble's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software, media and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee.

Francisco holds various FINRA licenses and an Accredited Senior Appraiser (ASA) designation from The American Society of Appraisers.

Joachim serves as Managing Director at Noble Capital Markets, where he leads the business development function. With extensive expertise in mergers and acquisitions, divestitures, and both pre- and post-deal services, he has successfully guided business owners and investors worldwide in executing complex deals across multiple industries.

Joachim has over 22 years combined experience as a professional in Business Development, M&A, and Public Accounting in the U.S. and Germany.

Before joining Noble Capital Markets, he was a business development executive at the Private Equity Group at CFGI, a portfolio company of Carlyle and CVC Capital, and prior to that he was heading the M&A practice for the New York region at a middle-market accounting advisory firm, and he spent several years at big four accounting firms in both the U.S. and Europe.